BioLine Rx Ltd (BLRX)
0.28
0.00 (0.00%)
USD |
NASDAQ |
Nov 25, 14:15
BioLine Rx Revenue (Quarterly): 5.393M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 5.393M |
March 31, 2024 | 6.855M |
December 31, 2023 | 4.80M |
September 30, 2023 | |
June 30, 2023 | |
March 31, 2023 | |
December 31, 2022 | |
September 30, 2022 | |
June 30, 2022 | |
March 31, 2022 | |
December 31, 2021 | |
September 30, 2021 | |
June 30, 2021 | |
March 31, 2021 | |
December 31, 2020 | |
September 30, 2020 | |
June 30, 2020 | |
March 31, 2020 | |
December 31, 2019 | |
September 30, 2019 | |
June 30, 2019 | |
March 31, 2019 | |
December 31, 2018 | |
September 30, 2018 | |
June 30, 2018 |
Date | Value |
---|---|
March 31, 2018 | |
December 31, 2017 | |
September 30, 2017 | |
June 30, 2017 | |
March 31, 2017 | |
December 31, 2016 | |
September 30, 2016 | |
June 30, 2016 | |
March 31, 2016 | |
December 31, 2015 | |
September 30, 2015 | |
June 30, 2015 | |
March 31, 2015 | |
December 31, 2014 | |
September 30, 2014 | |
June 30, 2014 | |
March 31, 2014 | |
December 31, 2013 | |
September 30, 2013 | |
June 30, 2013 | |
March 31, 2013 | |
December 31, 2012 | |
September 30, 2012 | |
June 30, 2012 | |
March 31, 2012 |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
4.80M
Minimum
Dec 2023
6.855M
Maximum
Mar 2024
5.683M
Average
5.393M
Median
Jun 2024
Revenue (Quarterly) Benchmarks
Compugen Ltd | 17.13M |
Pluri Inc | 0.326M |
XTL Biopharmaceuticals Ltd | -- |
Can Fite Biofarma Ltd | 0.155M |
BiomX Inc | -- |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | 0.484M |
Total Expenses (Quarterly) | 11.17M |
EPS Diluted (Quarterly) | 0.0061 |
Enterprise Value | 11.62M |
Gross Profit Margin (Quarterly) | 83.37% |
Profit Margin (Quarterly) | 8.97% |
Earnings Yield | -162.0% |